Chester County News and Community Website
MALVERN, PA — Venatorx Pharmaceuticals recently announced the addition of three seasoned executives to its senior team, signaling a significant pivot from its core research and development focus towards a …
Venatorx Pharmaceuticals Bolsters Leadership Team Amid Commercialization Push Read More MALVERN, PA — Venatorx Pharmaceuticals and Melinta Therapeutics recently received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) concerning their New Drug Application (NDA) for …
FDA Requests Additional Data for Venatorx and Melinta’s Antibiotic Combination Read More MALVERN, PA — Venatorx Pharmaceuticals, Melinta Therapeutics LLC, and the Menarini Group recently celebrated a significant medical breakthrough with the publication of the CERTAIN-1 Phase 3 clinical study results in …
Promising Phase 3 Results for Cefepime-Taniborbactam in Treating Complicated UTIs Read More MALVERN, PA — Venatorx Pharmaceuticals recently granted exclusive commercial rights to Italy’s Menarini Group for its novel antibiotic, cefepime-taniborbactam. The agreement extends to 96 countries in Europe, Latin America, Middle …
Venatorx Pharmaceuticals Strikes Deal with Menarini Group for Global Rights to Cefepime-Taniborbactam Read More MALVERN, PA — Venatorx Pharmaceuticals, a private, pre-commercial pharmaceutical company, announced the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within …
Venatorx Pharmaceuticals Awarded a Third Antibiotic BARDA Contract Read More MALVERN, PA — Venatorx Pharmaceuticals, a private, clinical-stage pharmaceutical company, announced seven presentations during IDWeek 2023, October 11-15, 2023, in Boston, MA for its novel antibiotics cefepime-taniborbactam and ceftibuten-ledaborbactam, including:
Venatorx Pharmaceuticals to Present at IDWeek 2023 Read More MALVERN, PA — Venatorx Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) recenlty accepted the company’s New Drug Application (NDA) for cefepime-taniborbactam, an investigational beta-lactam/beta-lactamase inhibitor (BL/BLI) antibiotic …
FDA Accepts Venatorx Pharmaceuticals’ New Drug Application for Cefepime-Taniborbactam Read More
MALVERN, PA — Venatorx Pharmaceuticals recently highlighted two recent publications that provide important updates on the changing epidemiology of carbapenem-resistant Enterobacterales (CRE) globally and in the United States (US). According …
The Rise of Metallo-Beta-Lactamases: Venatorx Pharmaceuticals Sheds Light on Carbapenem-Resistant Enterobacterales in the US Read More MALVERN, PA — Venatorx Pharmaceuticals announced recent changes to its Board of Directors. Tomas J. Heyman has been appointed to the Board of Directors in the newly created role of …
Venatorx Pharmaceuticals Appoints Tomas J. Heyman as Non-Executive Chairman Read More